Adaptation Dose of Enoxaparin in Moderate Renal Failure Patients With Acute Coronary Syndrome
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The objective of the VALIDE study is to validate that a 25% dose reduction of enoxaparine in
patients with moderate renal failure (creatinine clearance between 30 and 50 ml/min) and
hospitalized for an acute coronary syndrome provides at steady state a similar anti Xa level
in plasma compared to that obtained in patients without renal failure and receiving the usual
dose of 1 mg/kg subcutaneously every 12 hours. 140 per - protocol patients are planned to be
included.